Matinas BioPharma Holdings Inc (NYSEAMERICAN:MTNB) Director Patrick G. Lepore bought 100,000 shares of the stock in a transaction on Friday, August 16th. The stock was bought at an average price of $0.72 per share, for a total transaction of $72,000.00. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.
Matinas BioPharma stock opened at $0.67 on Friday. Matinas BioPharma Holdings Inc has a 1-year low of $0.40 and a 1-year high of $1.50.
Matinas BioPharma (NYSEAMERICAN:MTNB) last posted its quarterly earnings results on Tuesday, August 13th. The company reported ($0.03) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.04) by $0.01. The business had revenue of $0.09 million during the quarter, compared to analysts’ expectations of $0.06 million.
Several brokerages have weighed in on MTNB. HC Wainwright reiterated a “buy” rating and issued a $4.00 target price on shares of Matinas BioPharma in a research note on Wednesday, August 14th. BTIG Research began coverage on Matinas BioPharma in a research note on Friday, May 17th. They issued a “buy” rating and a $5.00 target price on the stock. Finally, Zacks Investment Research upgraded Matinas BioPharma from a “sell” rating to a “hold” rating in a research note on Wednesday, July 17th. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the company. The stock presently has an average rating of “Buy” and an average price target of $4.00.
Several institutional investors have recently bought and sold shares of the stock. BlackRock Inc. raised its holdings in Matinas BioPharma by 147.1% during the fourth quarter. BlackRock Inc. now owns 290,589 shares of the company’s stock worth $173,000 after purchasing an additional 173,005 shares during the last quarter. Northern Trust Corp raised its holdings in Matinas BioPharma by 18.9% during the fourth quarter. Northern Trust Corp now owns 182,641 shares of the company’s stock worth $109,000 after purchasing an additional 29,072 shares during the last quarter. Virtu Financial LLC raised its holdings in Matinas BioPharma by 80.0% during the first quarter. Virtu Financial LLC now owns 116,636 shares of the company’s stock worth $127,000 after purchasing an additional 51,853 shares during the last quarter. Brighton Jones LLC acquired a new position in Matinas BioPharma during the first quarter worth $55,000. Finally, Victory Capital Management Inc. acquired a new position in Matinas BioPharma during the first quarter worth $1,867,000.
About Matinas BioPharma
Matinas BioPharma Holdings, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of various product candidates. The company enables the delivery of life-changing medicines using its lipid nano-crystal (LNC) platform technology. Its LNC delivery technology platform utilizes lipid nano-crystals which can encapsulate small molecules, oligonucleotides, vaccines, peptides, proteins and other medicines potentially making them safer, more tolerable, less toxic, and orally bioavailable.
Read More: Which market index is the best?
Receive News & Ratings for Matinas BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Matinas BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.